Skip to main content
H

Hyundai ADM Bio lnc. — Investor Relations & Filings

Ticker · 187660 ISIN · KR7187660006 KO Professional, scientific and technical activities
Open in API
Filings indexed 249 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country KR South Korea
Listing KO 187660

About Hyundai ADM Bio lnc.

http://hdadmbio.com/eng/

Hyundai ADM Bio Inc. is a contract research organization (CRO) that provides comprehensive services for clinical trials. The company's offerings span the full clinical development lifecycle, including regulatory affairs, medical writing, clinical operations, project management, data management, and biostatistics. A primary research focus is in oncology, where the company has developed a novel approach to address drug 'pseudo-resistance'. This strategy involves selectively targeting Cancer-Associated Fibroblasts (CAFs) to enhance the delivery and efficacy of anticancer drugs by improving their access to tumor cells. The company supports various study phases and therapeutic areas, with a specialized emphasis on advancing cancer treatment methodologies.

Recent filings

Filing Released Lang Actions
주요사항보고서(유상증자결정)
Regulatory Filings
2026-04-30 Korean
증권신고서(지분증권)
Regulatory Filings
2026-04-30 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is titled “주식등의 대량보유상황보고서(일반)” which translates to a large shareholding status report under Korean capital markets law. It details the number of shares held, percentages, reporting dates, legal basis, and contract information for shareholders crossing significant ownership thresholds. This aligns exactly with our definition for Major Shareholding Notification (MRQ).
2026-03-26 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Correction Report' (정정신고) for a previously disclosed 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결). It details amendments to contract dates and confidentiality periods. Since this is a specific regulatory disclosure regarding a contract amendment and does not fit into categories like Annual Reports, Earnings Releases, or M&A, it falls under the general regulatory filing category.
2026-03-17 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the share ownership, changes in holdings, and collateral agreements (pledges) of major shareholders. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2026-03-12 Korean
[기재정정]주식매수선택권부여에관한신고
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from a Korean company (Hyundai ADM Bio) regarding the correction of a previously submitted report on the granting of stock options (주식매수선택권 부여에 관한 신고). It details the correction of exercise prices and fair value calculations for stock options granted to directors. Since this is a specific regulatory disclosure regarding corporate capital/equity structure changes (stock options) and does not fit into other categories like M&A or financial reports, it is classified as a general regulatory filing.
2026-03-10 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.